The third FDA-cleared Alzheimer's blood biomarker test in 2026 is C2N Diagnostics' PrecivityAD2, cleared on August 20, 2026, according to the Alzheimer's Association announcement. For younger-onset families, it offers a blood-based path to check for brain amyloid pathology, plus new choices around access, cost, and follow-up. A blood biomarker test measures blood proteins linked to Alzheimer's brain changes. PrecivityAD2 is for adults with cognitive signs or symptoms, used alongside medical history, exams, and cognitive testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Alz — Use this primary source to verify the official guidance.
Table of Contents
- Who qualifies starting at age 40?
- What does the blood test measure?
- How accurate is it and what are its limits?
- What does it cost and where is it available?
- Which follow-up questions should families ask?
Who qualifies starting at age 40?
PrecivityAD2 is indicated for adults age 40 and older with signs or symptoms of cognitive impairment, according to the C2N Diagnostics announcement. That age threshold matters because prior cleared tests were limited to age 55 and older. Younger-onset families often face years of uncertainty, so earlier eligibility can shorten the path to evaluation.
A clinician decides whether testing fits. Readers can check these basics before an appointment: Bring examples of symptoms, onset dates, work impact, and family history. That record helps the clinician judge whether biomarker testing is appropriate.
- age 40 or older
- memory, thinking, or functional changes now present
- order and interpretation through a licensed clinician
What does the blood test measure?
The test uses high-resolution mass spectrometry on a blood sample, according to C2N Diagnostics. It measures two plasma ratios: Aβ42/40 and p-tau217/np-tau217. Those ratios reflect amyloid-related processes in the brain.
Software converts the results into a score. The score helps rule in or rule out brain amyloid pathology. It does not by itself diagnose Alzheimer's disease.
How accurate is it and what are its limits?
FDA clearance drew on a 1,142-person study of symptomatic adults, reported by Welltica. Researchers compared PrecivityAD2 against amyloid PET imaging or cerebrospinal-fluid testing. Positive results showed about 97.6% predictive value for amyloid pathology.
The test is not approved as a screening or stand-alone diagnosis, according to AJMC. People without symptoms do not meet the indicated use. Other medical causes can also impair thinking and still need separate evaluation.
What does it cost and where is it available?
Reported U.S. pricing is about $1,000 out-of-pocket, with list-price trackers citing $1,450 against a CMS reimbursement benchmark around $130, according to the AInvest cost report. Families should verify coverage before ordering because self-pay and insurance payment can differ sharply. Ask the clinic for the exact order code, list price, and estimated patient amount in writing. Access runs through licensed clinicians, with wider U.S.
clinical availability expected later in 2026, according to C2N Diagnostics. A CLIA-validated laboratory-developed version remained available through C2N's St. Louis clinical laboratory. Anthem Blue Cross and Blue Shield announced first U.S. insurance medical-policy coverage for eligible members beginning October 1, 2026, according to the C2N Diagnostics release.
Which follow-up questions should families ask?
Ask whether a positive blood result needs confirmation with PET or cerebrospinal-fluid testing. Ask which other causes were ruled out, such as sleep apnea, depression, thyroid disease, vitamin deficiency, or medication effects.
Ask how results affect treatment options, trial eligibility, driving, work, and care planning. For younger-onset concerns, ask about referral to a memory specialist, genetic counseling when family pattern suggests it, and support services. Bring a symptom timeline, medication list, and a second person to take notes.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- The AAIC 2026 Swedish Real-World Blood Test Study: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
